scemblix 20 mg
novartis israel ltd - asciminib as hydrochloride - film coated tablets - asciminib as hydrochloride 20 mg - asciminib - scemblix is indicated for the treatment of adult patients with:• philadelphia chromosome-positive chronic myeloid leukemia (ph+ cml) in chronic phase (cp), previously treated with two or more tyrosine kinase inhibitors (tkis).• ph+ cml in cp with the t315i mutation
scemblix 40 mg
novartis israel ltd - asciminib as hydrochloride - film coated tablets - asciminib as hydrochloride 40 mg - asciminib - scemblix is indicated for the treatment of adult patients with:• philadelphia chromosome-positive chronic myeloid leukemia (ph+ cml) in chronic phase (cp), previously treated with two or more tyrosine kinase inhibitors (tkis).• ph+ cml in cp with the t315i mutation
ultibro breezhaler 11050 mcg
novartis israel ltd - glycopyrronium as bromide; indacaterol as maleate - inhalation powder hard capsules - indacaterol as maleate 110 mcg; glycopyrronium as bromide 50 mcg - indacaterol - ultibro breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd).
simbrinza
novartis israel ltd - brimonidine tartrate; brinzolamide - eye drops, suspension - brimonidine tartrate 2 mg/ml; brinzolamide 10 mg/ml - brinzolamide, combinations - decrease of elevated intraocular pressure (iop) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient iop reduction.
mayzent 2 mg
novartis israel ltd - siponimod as fumaric acid - film coated tablets - siponimod as fumaric acid 2 mg - siponimod - mayzent is indicated for the treatment of relapsing forms of multiple sclerosis (ms), to include relapsing-remitting disease, and active secondary progressive disease, in adults.
maxitrol ophthalmic suspension
novartis israel ltd - dexamethasone; neomycin as sulfate; polymyxin b sulfate - ophthalmic suspension - dexamethasone 1.0 mg/ml; neomycin as sulfate 3,500 iu/ml; polymyxin b sulfate 6000 iu/ml - polymyxin b - polymyxin b - maxitrol is indicated in ocular inflammation when concurrent use of antimicrobial in judged necessary.
maxitrol ophthalmic ointment
novartis israel ltd - dexamethasone; neomycin as sulfate; polymyxin b sulfate - ophtalmic ointment - dexamethasone 1 mg/g; neomycin as sulfate 3500 iu/g; polymyxin b sulfate 6000 iu/g - dexamethasone and antiinfectives - dexamethasone and antiinfectives - for the treatment of eye infections which are responsive to steroids, when an antibiotic is also needed.
duotrav
novartis israel ltd - timolol as maleate; travoprost - ophthalmic solution - travoprost 40 mcg/ml; timolol as maleate 5 mg/ml - timolol, combinations - timolol, combinations - decrease of intraocular pressure (iop) in patients with open angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.
azarga
novartis israel ltd - brinzolamide; timolol as maleate - ophthalmic suspension - brinzolamide 10 mg/ml; timolol as maleate 5 mg/ml - timolol, combinations - timolol, combinations - decrease of intra-ocular pressure (iop) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient iop reduction.
votrient 200 mg
novartis israel ltd - pazopanib as hydrochloride - film coated tablets - pazopanib as hydrochloride 200 mg - pazopanib - pazopanib - renal cell carcinoma (rcc)votrient is indicated in adults for the first line treatment of advanced renal cell carcinoma (rcc) and for patients who have received prior cytokine therapy for advanced disease.soft tissue sarcoma (sts)votrient is indicated for the treatment of adult patients with selective subtypes of advanced soft tissue sarcoma (sts) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy.